Zelira Therapeutics (ASX:ZLD) - Managing Director, Dr Richard Hopkins
Managing Director, Dr Richard Hopkins
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zelira Therapeutics (ZLD) will form a U.S. subsidiary to commercialise its hemp-derived cannabinoid-based oral care products
  • The first over-the-counter product will be launched this year, a cannabinoid- containing toothpaste developed by Sprinjene CEO and Founder Dr Sayed Ibrahim
  • The Zelia-Sprinjene products will be manufactured by Natural Beauty USA
  • Shares are trading 3.45 per cent higher at six cents

Zelira Therapeutics (ZLD) will form a U.S. subsidiary to commercialise its hemp-derived cannabinoid-based oral care products.

The first over-the-counter product will be launched this year, a cannabinoid- containing toothpaste developed by Sprinjene CEO and Founder Dr Sayed Ibrahim.

Sprinjene produces gluten-free, cruelty-free, vegan, kosher, USDA bio-preferred, and halal oral care products, which are manufactured by Natural Beauty USA.

Sayed said the Sprinjene team is excited about the partnership with Zelira.

“Our collaboration to commercialize the most advanced hemp-derived cannabinoid-based oral care products expands our reach into new oral care markets where every person can access the daily benefit of using our products,” he noted.

The Zelia-Sprinjene products will also be manufactured by Natural Beauty.

Zelia’s CEO and Managing Director in the U.S., Dr Oludare Odumosu, said the toothpaste is just one of five products the company expects to launch this year.

“Our products will be available for sale in the U.S. by the fourth quarter of 2020 and we remain focused on unlocking the benefits of cannabinoid-based applications as we expand our company’s reach into new and lucrative markets,” Oludare explained.

“This will be the first over-the-counter product line launched by Zelira,” he added.

Shares are trading 3.45 per cent higher at six cents at 10:20 am AEST.

ZLD by the numbers
More From The Market Herald

" Anatara Lifesciences (ASX:ANR) expands eligibility criteria for IBS and psychological functioning trials

Anatara Lifesciences (ASX:ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…

" Apiam Animal Health (ASX:AHX) executes growth strategy with two acquisitions

Apiam Animal Health (ASX:AHX) has announced new acquisitions as part of its growth strategy to double…

" Next Science (ASX:NXS) appoints Oraderm Pharmaceuticals as BlastX distributor

Next Science (ASX:NXS) has signed a multi-year distribution agreement for the sale and distribution of its…